Home » Stocks » ICPT

Intercept Pharmaceuticals, Inc. (ICPT)

Stock Price: $17.23 USD -0.52 (-2.93%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $17.63 +0.40 (2.32%) May 13, 6:35 PM
Market Cap 573.70M
Revenue (ttm) 321.70M
Net Income (ttm) -222.32M
Shares Out 33.16M
EPS (ttm) -6.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $17.23
Previous Close $17.75
Change ($) -0.52
Change (%) -2.93%
Day's Open 17.94
Day's Range 17.00 - 18.15
Day's Volume 717,439
52-Week Range 16.26 - 94.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations.

6 days ago - Zacks Investment Research

Intercept (ICPT) delivered earnings and revenue surprises of 20.26% and 1.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Worldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter

1 week ago - GlobeNewsWire

Analysts believe these underperformers could nearly double over the next 12 months.

Other stocks mentioned: INO, SRPT
1 week ago - The Motley Fool

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?

2 weeks ago - The Motley Fool

Analysts' consensus price targets imply that these stocks can more than double over the next 12 months.

Other stocks mentioned: NKLA, PLUG, SKLZ, VXRT
3 weeks ago - The Motley Fool

Hint: They're not AMC Entertainment, GameStop, or Sundial Growers.

Other stocks mentioned: FSLY, ROOT
1 month ago - The Motley Fool

Bargains abound for growth seekers and value investors.

Other stocks mentioned: CRWD, KL
1 month ago - The Motley Fool

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.

Other stocks mentioned: GILD, MDGL, NVS, PFE, TERN
1 month ago - The Motley Fool

You've probably never heard about these fast-paced companies before, but Wall Street believes they can make you a boatload of money.

Other stocks mentioned: CCHWF, ROOT
1 month ago - The Motley Fool

With the trading day nearing halfway over, the broad markets were somewhat mixed to close out the week.

Other stocks mentioned: JWN, NLSN, PYPL, CATM, CQP, KOD, MDB ...
2 months ago - 24/7 Wall Street

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pr...

2 months ago - GlobeNewsWire

Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.

2 months ago - Zacks Investment Research

Intercept (ICPT) delivered earnings and revenue surprises of -1.94% and -0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Worldwide Ocaliva ® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year

2 months ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets have pulled back from their recent all-time highs.

Other stocks mentioned: KSS, SPOT, XOM, FL, HEINY, MDLA, MGM ...
2 months ago - 24/7 Wall Street

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...

2 months ago - GlobeNewsWire

Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept's Executive Leadership Team

2 months ago - GlobeNewsWire

NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...

3 months ago - GlobeNewsWire

These bounce-back plays might be diamonds in the rough.

Other stocks mentioned: KGC, VLNCF
3 months ago - The Motley Fool

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...

4 months ago - GlobeNewsWire

Intercept has suffered an important set back with the FDA's CRL for Ocaliva in NASH with liver fibrosis. Ocaliva may still be approvable in NASH and the risk-reward for ICPT is more appealing at current...

4 months ago - Seeking Alpha

New York, New York--(Newsfile Corp. - January 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of In...

4 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 4, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...

4 months ago - Newsfile Corp

LOS ANGELES, Jan. 4, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. ("Int...

4 months ago - PRNewsWire

NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...

Other stocks mentioned: BSX, NAK
4 months ago - Accesswire

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ...

4 months ago - Business Wire

NEW YORK, Jan. 2, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) and certai...

4 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 2, 2021) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) betwee...

4 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...

4 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ICPT #classaction--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. (ICPT)

4 months ago - Business Wire

These companies are eager to say good riddance to the year that was.

Other stocks mentioned: AMRN, IVR, NGL, NXTC, PBF, SNDL, TCDA ...
4 months ago - The Motley Fool

New York, New York--(Newsfile Corp. - December 28, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...

4 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...

4 months ago - Business Wire

New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) betwe...

4 months ago - Newsfile Corp

NEW YORK, NY / ACCESSWIRE / December 28, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a...

Other stocks mentioned: BIIB, KNDI
4 months ago - Accesswire

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ...

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASD...

4 months ago - Newsfile Corp

NEW YORK, NY / ACCESSWIRE / December 24, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholde...

Other stocks mentioned: BABA, TILE
4 months ago - Accesswire

NEW YORK, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28...

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 24, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ:...

4 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 23, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...

4 months ago - Newsfile Corp

NEW YORK, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between Sept...

4 months ago - GlobeNewsWire

NEW YORK, NY / ACCESSWIRE / December 22, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to partic...

Other stocks mentioned: HPQ, RTX
4 months ago - Accesswire

NEW YORK, Dec. 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 20...

4 months ago - PRNewsWire

Investors with losses are encouraged to contact the firm before January 4, 2021; click here to submit trade information

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ:...

4 months ago - Newsfile Corp

About ICPT

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in vario... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2012
Stock Exchange
NASDAQ
Ticker Symbol
ICPT
Full Company Profile

Financial Performance

In 2020, ICPT's revenue was $312.69 million, an increase of 24.08% compared to the previous year's $252.00 million. Losses were -$274.88 million, -20.25% less than in 2019.

Financial Statements

Analyst Forecasts

According to 24 analysts, the average rating for ICPT stock is "Buy." The 12-month stock price forecast is 37.05, which is an increase of 115.03% from the latest price.

Price Target
$37.05
(115.03% upside)
Analyst Consensus: Buy